A Trim-RBD-GEM vaccine candidate protects mice from SARS-CoV-2

The SARS-CoV-2 pandemic has continued for about three years since emerging in late December 2019, resulting in millions of deaths. Therefore, there is an urgent need to develop a safe and effective vaccine to control SARS-CoV-2. In this study, we developed a bacterium-like particle vaccine that disp...

Descripción completa

Detalles Bibliográficos
Autores principales: Su, Rina, Shi, Zhuangzhuang, Li, Entao, Zhu, Menghan, Li, Dongxu, Liu, Xiawei, Sun, Yue, Feng, Na, Wang, Jianzhong, Wang, Tiecheng, Xia, Xianzhu, Sun, Weiyang, Gao, Yuwei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Inc. 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10266888/
https://www.ncbi.nlm.nih.gov/pubmed/37348143
http://dx.doi.org/10.1016/j.virol.2023.06.005
Descripción
Sumario:The SARS-CoV-2 pandemic has continued for about three years since emerging in late December 2019, resulting in millions of deaths. Therefore, there is an urgent need to develop a safe and effective vaccine to control SARS-CoV-2. In this study, we developed a bacterium-like particle vaccine that displays the SARS-CoV-2 receptor binding domain (RBD) (named Trim-RBD-GEM) using the GEM-PA system. We evaluated the immunogenicity and protective efficacy of the Trim-RBD-GEM vaccine with the oil-in-water adjuvant AddaVax in C57BL/6 N mice intramuscularly. We found that Trim-RBD-GEM&AddaVax induced high levels of humoral immunity in C57BL/6 N mice. Additionally, the lung virus loads in the immunized group were significantly decreased compared to the adjuvant control and mock groups. Therefore, this vaccine provides protection against lethal infection in a C57BL/6 N mouse model. Our Trim-RBD-GEM&AddaVax vaccine is potentially a promising, rapid, and safe subunit vaccine for preventing and controlling SARS-CoV-2.

Ejemplares similares